<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04049552</url>
  </required_header>
  <id_info>
    <org_study_id>HSC20190291H</org_study_id>
    <nct_id>NCT04049552</nct_id>
  </id_info>
  <brief_title>RAPA-Keloid Study of Keloid Regression</brief_title>
  <official_title>Effect of Topical Rapamycin Ointment on Keloid Regression: A Pilot Study in Human Subjects (RAPA-Keloid)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. To test whether topical rapamycin regresses established keloids in humans by measuring
           surface area and height changes in the scar over time (6 months)

        2. To test safety of product and feasibility of conduct for future clinical trial
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This pilot trial will use daily 0.5-1.0 ml applications of 8% RAPA (Rapamycin) in a
      petrolatum vehicle to treat established keloid lesions in 5 persons with at least 2 chronic
      keloids in similar body regions (greater than 1-year duration). Treatment will be applied
      once daily for 6 months. One keloid will receive 8% RAPA ointment and the other keloid will
      receive petrolatum-only ointment as a control. Surface areas and height of keloids will be
      monitored pre- and post-treatment to evaluate responses.

      Keloid surface area and height changes will be measured pre-treatment and thereafter on a
      monthly basis using standardized digital photography with a tripod-mounted 8MP Canon S5is
      camera and calipers to measure keloid height (37).

      Surface areas of all photographed lesions will be measured with Image J
      (http://rsbweb.nih.gov/ij/index.html), a public image-processing program that was used to
      analyze preliminary data and this study will use the same approach.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 24, 2020</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Study participants will serve as their own control, using intervention on one keloid and placebo on the other</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Keloid Surface Area</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Measurement of surface area of keloid</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Keloid Height</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Measurement of height of keloid</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Keloid</condition>
  <arm_group>
    <arm_group_label>RAPA intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rapamycin ointment will be applied to one keloid on the subject</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be applied as a control on one keloid on the subject</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rapamycin 8% Ointment</intervention_name>
    <description>A compounded ointment containing 8% rapamycin</description>
    <arm_group_label>RAPA intervention</arm_group_label>
    <other_name>Rapamycin ointment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Petrolatum ointment placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Petrolatum ointment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must have at least 2 keloid scars (for at least 1 year) in similar body
             locations that are easy to reach to apply ointment to

          -  Subject will be in good health with all chronic diseases (such as hypertension,
             coronary artery disease, etc.) clinically stable

          -  Cognitive functioning sufficient to provide informed consent

          -  Physically able to apply ointment to keloids daily

          -  Able to attend monthly clinic visits for 6 months

        Exclusion Criteria:

          -  Diagnosis of diabetes

          -  Subjects taking the following medications: systemic steroid or immunosuppressant
             therapy within the past 6 months

          -  Local area sterioidal treatment within the past 3 months

          -  History of allergy to rapamycin of petrolatum-based products
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dean L Kellogg Jr, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Health San Antonio</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dean L Kellogg, Jr, MD</last_name>
    <phone>210-617-5197</phone>
    <email>kelloggd@uthscsa.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Terry Romo, FNP-BC</last_name>
    <phone>210-949-3706</phone>
    <email>romot@uthscsa.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Audie L Murphy Memorial Veterans Hospital</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terri Romo, FNP-BC</last_name>
      <phone>210-949-3706</phone>
      <email>romot@uthscsa.edu</email>
    </contact>
    <contact_backup>
      <last_name>Beth Wu, BS</last_name>
      <phone>210-617-5300</phone>
      <phone_ext>15558</phone_ext>
      <email>wuy3@uthscsa.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 6, 2019</study_first_submitted>
  <study_first_submitted_qc>August 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2019</study_first_posted>
  <last_update_submitted>January 27, 2020</last_update_submitted>
  <last_update_submitted_qc>January 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keloid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Petrolatum</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

